Ginkgo Bioworks Holdings, Inc. (DNA): Shareholders' Equity
$508.59M
As of 2025-12-31
$420.28M
As of 2026-06-30
-33.6%
3-year compound annual growth
+2.0%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $508.59M | -29.0% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $716.06M | -34.7% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $1.10B | -36.8% | 2026-02-26, Balance as of period end |
| 2022-12-31 | $1.74B | +15.3% | 2023-03-13, Balance as of period end |
| 2021-12-31 | $1.51B | +226.3% | 2023-03-13, Balance as of period end |
| 2020-12-31 | $461.38M | n/a | 2022-03-29, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $508.59M | -29.0% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $102.73M | -60.4% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $11.85M | -70.0% |
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $1.24B | +68.8% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $233.06M | +4.5% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $87.80M | +49.0% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | -$38.50M | n/m |
| Agenus Inc (AGEN) | 2025-12-31 | -$271.11M | n/m |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | -$500.47M | n/m |
Compare DNA, RGNX, ADAPY, BEAM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗